ImmuneWalk Therapeutics Inc
Clinical-stage biotechnology company developing therapies for immune-inflammatory indications based on discovery of a myeloid-cell adhesion checkpoint that controls monocyte and neutrophil entry into inflamed tissues. The lead clinical-stage candidate is a monoclonal antibody therapeutic designed to prevent myeloid cell migration; a first-in-human Phase 1 trial (randomized, blinded, placebo-controlled SAD/MAD) is ongoing. Preclinical efficacy has been reported in models of multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and metabolic dysfunction-associated steatohepatitis.
Industries
Nr. of Employees
small (1-50)
ImmuneWalk Therapeutics Inc
Pearl River, New York, United States, North America
Patents
Motile sperm domain containing protein 2 antibodies and methods of use thereof
US-11697682-B2
View Details
Motile sperm domain containing protein 2 antibodies and methods of use thereof
US-11697682-B2
View DetailsProducts
Clinical-stage monoclonal antibody therapeutic targeting a myeloid adhesion checkpoint
A clinical-stage monoclonal antibody candidate engineered to inhibit a myeloid-cell adhesion checkpoint and prevent monocyte and neutrophil entry into inflamed tissues; being evaluated in a first-in-human Phase 1 SAD/MAD trial with PK/PD and biomarker endpoints.
IW-601
IW-601 is a subcutaneous immunomodulator evaluated in the POINTGUARD first-in-human clinical trial for safety, tolerability, pharmacokinetics, and pharmacodynamics.
Clinical-stage monoclonal antibody therapeutic targeting a myeloid adhesion checkpoint
A clinical-stage monoclonal antibody candidate engineered to inhibit a myeloid-cell adhesion checkpoint and prevent monocyte and neutrophil entry into inflamed tissues; being evaluated in a first-in-human Phase 1 SAD/MAD trial with PK/PD and biomarker endpoints.
IW-601
IW-601 is a subcutaneous immunomodulator evaluated in the POINTGUARD first-in-human clinical trial for safety, tolerability, pharmacokinetics, and pharmacodynamics.
Expertise Areas
- Clinical trial management (early-phase SAD/MAD)
- Myeloid-targeted immunology
- Monoclonal antibody therapeutic development
- Preclinical disease modeling for inflammatory indications
Key Technologies
- Monoclonal antibody therapeutics
- Myeloid cell adhesion checkpoint targeting
- β2-integrin modulation mechanism
- Preclinical animal disease models (MS, RA, IBD, NASH/MASH)
News & Updates
The Phase 1 Single Ascending Dose stage of the first-in-human trial met safety, tolerability, PK and PD endpoints.
Announcement of $7 million seed financing for the company.
Company presented therapeutic candidate data at industry events including a 2025 BIO convention presentation and other conference posters.
Company CEO scheduled to present at industry events (e.g., Longwood MIT CEO 2025).
The Phase 1 Single Ascending Dose stage of the first-in-human trial met safety, tolerability, PK and PD endpoints.
Announcement of $7 million seed financing for the company.
Company presented therapeutic candidate data at industry events including a 2025 BIO convention presentation and other conference posters.
Company CEO scheduled to present at industry events (e.g., Longwood MIT CEO 2025).